UCLA Health researchers unveil major advances in breast cancer AI pathology, liquid biopsy, and biomarker strategies at the 2025 SABCS.
Key Details
- 12025 San Antonio Breast Cancer Symposium features UCLA-led research in early detection, precision medicine, and artificial intelligence.
- 2A study of 2,200+ breast cancer cases showed an AI tool (Ataraxis Breast) surpassed current criteria in identifying high-risk HR+/HER2– patients for CDK4/6 therapy.
- 3Research using liquid biopsy (ctDNA) found negative results were linked to less anxiety and greater well-being in survivors.
- 4Simple immune blood markers before treatment predicted pathologic response to neoadjuvant immunotherapy in triple-negative breast cancer.
- 5AI-driven pathology may refine treatment selection, and liquid biopsies show promise in both outcomes tracking and patient support.
Why It Matters
These advances suggest AI and blood-based diagnostics may dramatically improve risk stratification, treatment selection, and quality of life in breast cancer care. The findings point to imminent shifts in clinical workflows and highlight the growing role of artificial intelligence in precision oncology.
Source
EurekAlert
Related News
•EurekAlert
MD Anderson Unveils New AI Genomics Insights and Therapeutic Advances
MD Anderson reports breakthroughs in cancer therapeutics and provides critical insights into AI models for genomic analysis.
•EurekAlert
SH17 Dataset Boosts AI Detection of PPE for Worker Safety
University of Windsor researchers released SH17, a 8,099-image open dataset for AI-driven detection of personal protective equipment (PPE) in manufacturing settings.
•EurekAlert
Future of Large Language Models in Cardiovascular Imaging Explored
Large language models are poised to advance cardiovascular imaging through workflow optimization, interpretation, and ethical innovation across modalities.